ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Virginia's MULTIDISCIPLINARY CANCER CARE TEAMs and the PATIENTS THEY SERVE since 1990
Meetings & Education
Financial Advocacy & Patient Assistance
VAHO Advocacy Support
Patient Advocacy Organizations
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
National Professional organizations
VAHO Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Pembrolizumab for Advanced Cervical Cancer
On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck and Co. Inc.) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
Read the full FDA press release here.
Tweets by OSSatACCC